BIBLIOS

  Sistema de Gestão de Referências Bibliográficas de Ciências

Modo Visitante (Login)
Need help?


Voltar

Detalhes Referência

Tipo
Capítulo em Livro


Título
Recent Advances on SGLT 2 Inhibitors: Synthetic Approaches, Therapeutic Benefits, and Adverse Events

Participantes na publicação
Ana M. Matos (Author)
FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA
CQE
Patrícia Calado (Author)
FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA
William Washburn (Author)
Amélia P. Rauter (Author)
FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA

Resumo
Diabetes mellitus comprises serious metabolic disorders currently affecting almost 500 million people globally – an estimate predicted to rise up to approximately 700 million by 2045. With time, permanently high blood sugar levels caused either by autoimmune destruction of pancreatic beta cells (type 1 diabetes) or peripheral insulin resistance (type 2 diabetes) may lead to cardiovascular complications, kidney damage, among other causes of high morbidity and mortality among diabetic patients. SGLT2 inhibitors are the most recent class of antidiabetic drugs approved by regulatory authorities and have recently been associated with remarkable clinical outcomes in patients with diabetes and related comorbidities. This multidisciplinary review chapter covers the most recent and innovative synthetic approaches for the generation of gliflozin SGLT2 inhibitors, together with the newest results of clinical trials and real-world evidence studies, with special focus on the years of 2019 and 2020. Up-to-date data on glycemic control, cardioprotective and renoprotective effects of SGLT2 inhibitors are herein explored, as well as common adverse events experienced by patients in the course of their treatment, both in the context of type 1 and type 2 diabetes.

Editor
J. Fischer, C. Klein, W.E. Childers

Data de Publicação
2021-02-26

Instituição
FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA

Suporte
Successful Drug Discovery

Identificadores da Publicação

Editora
Wiley

Edição
1st
Volume
5

Número de Páginas
46
Página Inicial
111
Página Final
157

Identificadores do Documento
DOI - https://doi.org/10.1002/9783527826872.ch4
URL - http://dx.doi.org/10.1002/9783527826872.ch4

Keywords
gliflozin-type SGLT2 inhibitors synthesis mechanism of action clinical benefits HbA1C levels cardiovascular protection renoprotection bodyweight reduction adverse effects type 1 diabetes


Exportar referência

APA
Ana M. Matos, Patrícia Calado, William Washburn, Amélia P. Rauter, (2021). Recent Advances on SGLT 2 Inhibitors: Synthetic Approaches, Therapeutic Benefits, and Adverse Events. Successful Drug Discovery, 111-157

IEEE
Ana M. Matos, Patrícia Calado, William Washburn, Amélia P. Rauter, "Recent Advances on SGLT 2 Inhibitors: Synthetic Approaches, Therapeutic Benefits, and Adverse Events" in Successful Drug Discovery, 2021, pp. 111-157

BIBTEX
@incollection{48729, author = {Ana M. Matos and Patrícia Calado and William Washburn and Amélia P. Rauter}, title = {Recent Advances on SGLT 2 Inhibitors: Synthetic Approaches, Therapeutic Benefits, and Adverse Events}, booktitle = {Successful Drug Discovery}, year = 2021, pages = {111-157}, address = {}, publisher = {Wiley} }